Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

In this randomized, controlled, multicenter, international trial, 7376 patients with moderate to very severe COPD who ... with more mild disease or those without previous exacerbations.

Depending on your FEV1 and FVC readings, your doctor will stage your COPD based on the following: The first stage is considered ... of COPD exacerbation are also common in severe COPD.

FET or huff FET; huff The FET involves carefully exhaling with the mouth and glottis open to generate mild dynamic ... Acute exacerbation of chronic obstructive pulmonary disease; COPD: Chronic ...

and had ≥2 moderate to severe COPD exacerbations in the past 12 months. Participants were randomly assigned (1:1) to receive either 420 mg tezepelumab or placebo subcutaneously every 4 weeks for up to ...

A study was undertaken to investigate the sputum cell and cytokine characteristics of COPD when stable and during an exacerbation. METHODS Induced sputum samples from 57 patients with moderate to ...

exacerbation history categories in estimating moderate and severe exacerbations of chronic obstructive pulmonary disease (ECOPD) and all-cause mortality in patients with COPD. Conducted using data ...

Main outcome measures In this 1:1 propensity score matched study, the main outcome measures were first moderate or severe COPD exacerbation (effectiveness) and first admission to hospital with ...

In the MANDALA trial, Airsupra was found to significant reduce the risk of severe exacerbations compared ... in patients with mild to moderate asthma. In terms of safety and tolerability, in ...